daunorubicin has been researched along with Lupus Erythematosus, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarado de la Barrera, C; Diaz-Borjon, A; Jakez-Ocampo, J; Llorente, L; Richaud-Patin, Y; Ruiz-Argüelles, A | 1 |
| Abe, T; Amano, K; Homma, M; Hosono, O; Koide, J; Masuho, Y; Morimoto, C; Takano, M; Takeuchi, T | 1 |
2 other study(ies) available for daunorubicin and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Count; Daunorubicin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Flow Cytometry; Genes, MDR; Humans; Lupus Erythematosus, Systemic; Lymphocytes; Male; Monocytes; Prednisone; Severity of Illness Index; Verapamil | 2000 |
DNA-daunorubicin complexes specifically suppress in vitro spontaneous anti-DNA antibody production in lymphocytes of patients with systemic lupus erythematosus.
Topics: Antibodies, Antinuclear; Concanavalin A; Daunorubicin; DNA; DNA Adducts; Humans; In Vitro Techniques; Lupus Erythematosus, Systemic; Lymphocyte Activation; Lymphocytes; Phytohemagglutinins | 1986 |